freeze-dried powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
These values are much greater than the oxide's, but still a few orders of magnitude lower than those of pristine graphene. Recently, the synthetic protocol for graphite oxide was optimized and almost intact graphene oxide with a preserved carbon framework was obtained. Reduction of this almost intact graphene oxide performs much better and the mobility values of charge carriers exceeds 1000 cm2/Vs for the best quality of flakes. Inspection with the atomic force microscope shows that the oxygen bonds distort the carbon layer, creating a pronounced intrinsic roughness in the oxide layers which persists after reduction. These defects also show up in Raman spectra of graphene oxide. Large amounts of graphene sheets may also be produced through thermal methods. For example, in 2006 a method was discovered that simultaneously exfoliates and reduces graphite oxide by rapid heating (>2000 °C/min) to 1050 °C. At this temperature, carbon dioxide is released as the oxygen functionalities are removed and it explosively separates the sheets as it comes out. The temperature of reduction is important for the oxygen content of the final product, with higher degree of reduction for higher reduction temperatures. Exposing a film of graphite oxide to the laser of a LightScribe DVD has also revealed to produce quality graphene at a low cost. Graphene oxide has also been reduced to graphene in situ, using a 3D printed pattern of engineered E. coli bacteria. Coupling of graphene oxide with biomolecules such as peptide, proteins and enzymes enhances its biomedical applications.
As such, unlike in 2023 when the junta-appointed Senate (whose term also ends after five years) blocked the election's winner from forming government, this time the outcome of the election should determine the resulting government.
Simon Hale – arrangements and conductor Gavyn Wright – string leader Marc Scully – double bass David Daniels and Mick Stirling – cello Rachel Bolt, Gustav Clarkson and Bruce White – viola Rebecca Hirsch, Patrick Kiernan, Boguslaw Kostecki, Julian Leaper, Jackie Shave, Katherine Shave and David Woodcock – violin
Large randomised controlled trials have shown that dapagliflozin significantly reduces worsening heart failure and heart failure hospitalisation across the spectrum of heart failure, including patients with reduced ejection fraction (LVEF <40%), mildly reduced ejection fraction (LVEF 41–49%) and preserved ejection fraction (LVEF ≥50%). Research shows that early initiation during hospitalization for acute heart failure appears safe in stable patients. Combined results of multiple trials also found that starting SGLT2 inhibitors in the hospital significantly lowers the risk of death from heart problems and prevents heart failure from getting worse. Dapagliflozin and other SGLT2 inhibitors may reduce hospitalisation for heart failure in Type 2 diabetic patients, with or without atherosclerotic cardiovascular disease,however evidence across these patient groups remains incomplete. Some meta-analyses and cohort studies have demonstrated consistent efficacy among SGLT2 inhibitors in reducing specific heart failure hospitalization, but there are no direct and definitive studies indicating the superiority of dapagliflozin over other SGLT2 inhibitors like empagliflozin and further studies are needed to support this claim In the European Union, dapagliflozin is indicated in adults for treatment of:
Sources: en.wikipedia.org
Reek of Putrefaction is the debut studio album by English extreme metal band Carcass. It was released by Earache Records on 28 July 1988. It is considered the first release in the goregrind genre, which the band pioneered.
== Function == The trachea's main function is to transport air to and from the lungs. It also helps to warm, humidify, and filter the air before it reaches the lungs. The trachea is made up of rings of cartilage, which help to keep it open and prevent it from collapsing. The inside of the trachea is lined with a mucous membrane, which produces mucus to help trap dirt and dust particles. The cilia, which are tiny hairs that line the mucous membrane, help to move the mucus and trapped particles up and out of the trachea.
== SE == se – (s) Northern Sami language (ISO 639-1 code) Se – (s) Selenium SE (s) Seychelles (FIPS 10-4 country code) (i) Societas Europaea (form of business organization in the EU) South-east (s) Sweden (ISO 3166 digram) (i) Synthetic Environment Systems engineering SEAD – (i) Suppression of Enemy Air Defence(s) SEADI – (i) Senior Executioner of Approved Driving Instructors SEAFDEC – (p) Southeast Asian Fisheries Development Center SEAL – (p) SEa-Air-Land SEAT – (a) Sociedad Española de Automóviles de Turismo (Spanish for "Spanish Touring Car Company") SEATO – (a) Southeast Asia Treaty Organization SeaWiFS – (p) Sea-Viewing Wide Field of View Sensor (satellite instrument) SEC (i) U.S. Securities and Exchange Commission (p) Security Southeastern Conference SECaaS - (p) Security-as-a-Service SECAM – (a) Séquentiel couleur à mémoire (French for "Colour Sequential with Memory"; TV standard, cf. NTSC, PAL) SECDEF – (p) (U.S.) Secretary of Defense SED – (i) CERDEC Software Engineering Directorate SEDRIS – (a) Synthetic Environment Data Representation and Interchange Specification SEE – (a) Small Emplacement Excavator SEG – (i) Society of Exploration Geophysicists SEG – (i) Special Escort Group SEK – (s) Swedish krona (ISO 4217 currency code) Selkent – (p) South East London & Kent Bus Company SELT – (a) Single Ended Line Test (ing) SEM (i/a) Sensor Employment Manager Switch to Email Mode, i.e.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.